Novo and Roche are in line for exits from hepatitis drug developer Aligos Therapeutics, which has raised some $230m since it was founded in 2018.

Aligos Therapeutics, the US-based small molecule drug developer backed by corporates Roche and Novo, has set the terms for an initial public offering that would raise $160m at the top of its range. The offering is set to consist of 10 million shares issued on the Nasdaq Global Market and priced between $14 and $16…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.